 |
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
|
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
DISEASE OF THE MONTH |
Nephrology Research and Training Center, Division of Nephrology, Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama.
Correspondence to Dr. Stephen G. Rostand, Division of Nephrology, Department of Medicine, 604 Zeigler Building, 1530 3rd Avenue South, Birmingham, AL 35294. Phone: 205-934-2646; Fax: 205-975-6154; E-mail: srostand{at}nrtc.dom.uab.edu
 |
Introduction |
|---|
 Top Introduction CAD Risk Factors in...Silent Ischemia, Occult CAD,...ConclusionReferences |
|---|
A partial explanation for these observations may come from the demographic characteristics of ESRD populations. Increased age is an important unmodifiable demographic factor associated with cardiovascular risk. During the past 15 yr, the median incident age of patients with ESRD in the United States has increased by more than a decade, from 53 yr in 1980 to 64 yr in 1995. Patients older than age 65 now represent nearly 68% of all new dialysis patients. Moreover, during the same time period, the greatest percentage increase in incidence of ESRD (nearly sevenfold) was seen in the those age 75 and older. As a result, there are nearly triple the number of those age 65 and older in dialysis populations than are in the general U.S. population (3). Because CVD is seen more commonly in older populations, it is not surprising that there is a high prevalence of preexisting comorbid cardiovascular conditions in new ESRD patients. Thus, for example, in 1997, 34.7% had a history of congestive heart failure, 25.1% had a history of coronary artery disease (CAD), 9.4% had a history of coronary myocardial infarction, and 15.6% had a history of coronary peripheral vascular disease, a surrogate marker for CAD (4). Such preexisting cardiovascular conditions have long been known to adversely affect ESRD survival.
Other important risks for fatal and nonfatal cardiovascular events are the diseases that cause ESRD. Of these, hypertension and diabetes mellitus, which cause 70% of all ESRD in the United States, are strongly associated with the development of CVD, particularly CAD, whose attendant ischemia not only can produce acute coronary syndromes but also can contribute significantly to other cardiac disorders. For example, it is know to be the underlying basis for 70% of congestive heart failure (5). Though seen less often as causes of renal failure, systemic lupus erythematosus, vasculitides, and atherosclerotic renal disease, resulting either from direct effects on the vasculature or from the effects of steroid therapy, are strongly associated with the presence of CAD as is the nephrotic syndrome. However, although age, hypertension, and diabetes are important risks for CVD in ESRD populations, present data reveal that increased rates of cardiovascular mortality are seen across all age groups (1). When the results of current studies are compared with ones done in an era when the median age of ESRD patients was less than 40 yr and when diabetics were largely excluded from dialysis and transplantation but also showed high cardiovascular mortality, one must conclude that demographics alone cannot explain the predilection for CAD events in ESRD.
|
CAD Risk Factors in Renal Failure and the Effects of Their Modification |
|---|
|
TopIntroductionCAD Risk Factors in...Silent Ischemia, Occult CAD,...ConclusionReferences |
|---|
|
Dyslipoproteinemia
Lipoprotein abnormalities are the most often discussed established CAD risk
factors seen in renal failure. Hypertriglyceridemia is most commonly observed
in ESRD but has a weaker statistical association with CAD than other
frequently noted lipoprotein abnormalities
(6), such as elevated total
serum cholesterol, VLDL, LDL, IDL, Lp (a), and apolipoprotein CIII and reduced
HDL and apolipoproteins AI, AII, and AIII. The extent of these changes depends
on the duration and severity of renal insufficiency because these
abnormalities become more apparent as renal deterioration advances
(7). Moreover, their
pathophysiologic significance may vary with race and gender
(8,9).
Factors that contribute to uremia-associated dyslipoproteinemia include obesity, diabetes mellitus, uremic glucose intolerance, hyperparathyroidism (HPTH), reduced active vitamin D metabolites, early menopause (in the case of women), and possibly carnitine deficiency that impairs fatty acid metabolism.
There is consensus that treatment of dyslipidemia in non-ESRD populations can lead to stabilization and even regression of atherosclerotic plaque and to a reduction of fatal and nonfatal myocardial ischemic events over time periods ranging from 6 mo to 2 yr or more (10,11). Although there is little question that lipid-lowering agents can favorably modify lipoprotein concentrations in both non-ESRD and ESRD populations, unlike non-ESRD populations, there is no evidence to show reductions of cardiovascular events in renal failure (12). Perhaps the inability to see such benefits relates to fact that it may take as long as 2 to 5 yr to see a decrease in cardiovascular events, barely enough time to see such improvements in ESRD patients whose 5-yr survival on dialysis is only 40 to 50% (4). Nevertheless, because lipoprotein abnormalities are observed early in the course of progressive renal deterioration, it seems more likely that intervention at a time well before the patient approaches ESRD may yield the best results. Fibric acid derivatives, bile sequestrants, omega-3 polyunsaturated fatty acids, and nicotinic acid have been used to correct dyslipoproteinemia in ESRD, but the best tolerated are the statin drugs. Studies that tested the effects of L-carnitine supplementation showed that although blood carnitine levels could be restored, there were no significant effects on lipid profiles (13).
Hypertension
Hypertension is a well-established risk factor not only for myocardial
ischemia, atherogenesis, and coronary artery calcification but also for the
development of left ventricular hypertrophy (LVH). By contributing to LVH,
hypertension represents an important risk for sudden cardiac death. Forces on
arterial and aortic walls produced by increased BP alter vascular endothelial
cell function by inciting arterial oxidative stress and inflammatory
responses. These effects in turn initiate the atherosclerotic process and
stimulate various growth-promoting peptides
(14). The attendant
endothelial dysfunction can lead to hypertrophy, hyperplasia, lipid
incorporation, and calcification of the vascular smooth muscle and to
associated reductions in vascular compliance and thus to tissue ischemia. The
reduced elasticity of the aorta and peripheral arteries further contributes to
increased cardiac work, LVH, and increased cardiovascular mortality in ESRD
patients (15).
Because hypertension is a major hazard for CAD and stroke and because BP reduction can reduce the risk for myocardial infarction, it is disheartening that BP is not particularly well controlled in ESRD patients (16). This may be due to numerous factors, including medication cost, lack of patient compliance and education about their medications, selection of an inappropriate dry weight, excess interdialytic weight gain, sub-optimal therapy, and withholding antihypertensive medications before dialysis. Whatever the reasons, efforts to improve BP need to be intensified. In this regard, the use of ambulatory BP monitoring may be of great use because it allows a more comprehensive assessment of daily variations of BP than single measurements and therefore may be better in helping to determine the best antihypertensive strategies.
Many drugs are available for the task. Recently published data from the Heart Outcomes and Prevention Evaluation study (17) suggest that in high-risk patients, the use of an angiotensin-converting enzyme inhibitor (ACEI) significantly reduces death rates for stroke, myocardial infarction, and all cardiovascular causes, effects that could not be attributed simply to BP lowering. Thus, drugs of this class may be beneficial in ESRD patiebnts, especially if hyperkalemia does not become a problem. The use of ß-blockers may also have a beneficial effect in this group who either have or are at high risk for developing cardiovascular complications. In addition, there may be a theoretical benefit from using calcium channel blockers because they have been shown in animal studies to decrease intravascular and myocardial calcium content (18).
Left Ventricular Hypertrophy
LVH is an important risk factor for death after myocardial infarction; LVH
and increased left ventricular mass index are the most common structural
abnormalities of the heart seen in renal failure. LVH can be attributed in
large part but not exclusively to the effects of hypertension. The high
prevalence of LVH in ESRD populations may well account for their observed
excess fatal coronary heart disease events, for in addition to increased
coronary mass there is a reduced density of capillaires with respect to
cardiomyocytes as well as an increase of the wall to lumen ratios of
intramyocardial arterioles
(19,20).
Such changes can decrease myocardial tolerance to ischemia by creating an
imbalance between oxygen supply and demand. This may contribute to the
decreased coronary vasodilator reserve noted with LVH and may also explain the
25 to 30% prevalence of myocardial ischemia seen in ESRD patients who have no
anatomically significant coronary event documented by angiography
(9).
Secondary HPTH, elevated levels of endothelin, and other inhibitors of nitric oxide synthesis may also contribute to altered endothelial and cardiomyocyte growth and function. It seems reasonable that coronary vasodilators, e.g., nitrates, calcium channel blockers, and estrogens, or drugs that improve endothelial function such as lipid lowering agents and ACEI may be beneficial. ACEI may also produce regression of LVH. Although regression of LVH may be associated with lower cardiac mortality, such regression is infrequently seen in ESRD. If such a benefit is to be derived, as with therapy for dyslipoproteinemia, early intervention with antihypertensive agents may ultimately be most effective. At present, however, there is no evidence for such benefits in the ESRD population.
Anemia
Anemia contributes to myocardial ischemia by producing high cardiac output
and increased cardiac work, reduced coronary artery filling times, reduced
myocardial oxygen delivery, and reduced coronary artery dilator reserve. These
effects are additive to those of LVH. It now is well established that
treatment of uremic anemia with erythropoietin can improve cardiac performance
(21). Although correction of
hematocrit to concentrations above 30% has improved the well-being of most
patients undergoing renal replacement therapy and may have decreased the
number of anginal episodes, there are no studies to show that the number of
other fatal and nonfatal cardiac events has been reduced.
Diabetes Mellitus and Carbohydrate Intolerance
Diabetes mellitus is the most common cause of renal failure in the United
States and is associated not only with hypertension but also with
hypertriglyceridemia and hypercholesterolemia—elevated LDL and depressed
HDL cholesterol concentrations—with LVH and with hyperfibrinogenemia.
Moreover, chronic renal failure, independent of diabetes mellitus, is also
associated with insulin resistance and glucose intolerance. Both are
associated with the accumulation of advanced glycation end products that may
induce cellular activation and endothelial damage, ultimately contributing to
or even accelerating atherogenesis
(22).
There is considerable evidence that aggressive glucose control can significantly reduce microvascular and macrovascular complications of diabetes. Therefore, it is important not only to manage diabetes aggressively before the onset of renal disease but also to continue rigorous glycemic control after ESRD has developed. Because hypoglycemic reactions are more common in renal failure, there is a tendency for nephrologists and others who care for diabetics with ESRD to allow blood glucose concentrations to remain at levels that would be unacceptable in the absence of renal failure, thus sustaining the risk for vascular damage and atherogenesis. Sustained rigorous glycemic control before the onset, as well as after the initiation, of renal replacement therapies may be important in reducing cardiovascular morbidity and mortality in diabetic patients as has been shown by Wu et al. (23). However, whether such benefits would be offset by excessive hypoglycemic complications needs to be investigated further.
Altered Pituitary-Gonadal Axis
It has long been observed that women who develop ESRD have abnormal
menstrual cycles; they either cease menstruating or menstruate infrequently,
and they often fail to ovulate. Thus, women with ESRD seem to have premature
menopause and, as a result, may be at cardiovascular risk earlier than
postmenopausal women in the non-ESRD population. Women with ESRD have symptoms
of ischemic heart disease and significant anatomic CAD with a greater
frequency than women without ESRD, but still their high rates of CAD and
symptoms of myocardial ischemia are less than those of men
(8). Nevertheless, these
findings suggest that women with ESRD may have accelerated atherosclerosis and
may benefit from estrogen replacement therapy. In this regard, the HERS Trial
described a late benefit of estrogen replacement in postmenopausal women
(24). Thus, it may be that
estrogen replacement therapy in women with renal failure may reduce coronary
artery risk; however, Stehman-Breen et al.
(25) observed that estrogen
replacement therapy is prescribed less frequently in ESRD than in non-ESRD
women. Recent studies have found that treatment of postmenopausal women with
ESRD using estradiol could increase HDL cholesterol and apolipoprotein
A1
(26,27).
Although such improvements may confer protection, once again there are no
large-scale studies showing coronary events to be decreased
(26). Conjugated estrogen may
also be beneficial because of its effects as a coronary vasodilator, but this
effect may be countered by its stimulation of vascular smooth muscle
calcification (28). Perhaps
this might in part contribute to the early increase in cardiovascular events
noted in the HERS study (24).
Thus, the impact of estrogen replacement therapy on preventing cardiovascular
events in ESRD remains to be determined.
Hyperhomocysteinemia
Hyperhomocysteinemia has emerged as an important risk factor for fatal and
nonfatal coronary events (29).
In patients with established CAD, it is also a strong predictor of mortality
(30). Homocysteine has been
shown to enhance neutrophilendothelial interactions and impair
endothelium-dependent vasodilatation. As in the general population,
hyperhomocysteinemia is seen with high prevalence and has been found to be an
independent predictor of CVD events in renal failure
(31).
Homocysteine metabolism is critically dependent on vitamin B6, vitamin B12, and folic acid; thus, deficiencies in these vitamins could limit homocysteine metabolism and produce hyperhomocysteinemia. In renal failure, poor nutrition coupled with removal of water-soluble vitamins by dialysis may partially explain a tendency to deficiencies of these vitamins and the high prevalence of hyperhomocysteinemia. In non-ESRD populations, treatment with folic acid alone or in combination with vitamins B12 and B6 has been shown to lower homocysteine levels, but to date no clinical, randomized trials measuring the effects of lowering homocysteine levels on cardiovascular events have reported their results. In renal failure, most patients are prescribed multivitamins with enough folic acid to reduce homocysteine, at least in nonuremic subjects. Thus, current folic acid supplementation regimens may be inadequate in renal failure because hyperhomocysteinemia and excess cardiovascular events persist.
Calciotropic Hormone and Calcium/Phosphorus Dysregulation
HPTH, hypovitaminosis D, and hyperphosphatemia are nearly universally found
in ESRD and develop progressively as renal function deteriorates. Although
these alterations are most often considered in the context of renal
osteodystrophy, there is a growing body of evidence to support the view that
elevated parathyroid hormone (PTH), reduced production of active vitamin D
metabolites, altered tissue responsiveness to these hormones, sustained
hyperphosphatemia, and the aggressive use of calcium supplements and vitamin D
analogs are important in the pathogenesis and maintenance of CVD in chronic
renal failure (32). Both PTH
and vitamin D increase the calcium concentration of vascular smooth muscle and
cardiac myocytes, thereby altering myocardial oxidative metabolism and
affecting BP, cardiac contractility, and force generation. This can cause the
heart to be more critically dependent on oxygen and, thus, more susceptible to
ischemia. Vitamin D depletion can produce vascular smooth muscle cell growth
and proliferation, and hypovitaminosis D is associated with coronary artery
calcification, a phenomenon that has recently been found to be exuberant in
human uremic hearts when compared with nonuremic hearts
(33,34).
In this regard, in renal failure, HPTH is associated with reduced luminal
diameter of small intramyocardial arteries. Vitamin D deficiency and HPTH can
produce increased cardiac mass and are associated strongly with heart valve
calcification, and HPTH is associated with myocardial fibrosis and
calcification. In renal failure, HPTH has been shown to affect adversely
lipoprotein metabolism and to produce insulin resistance and glucose
intolerance. A role for vitamin D is less clear, but 1,25(OH2)
D3 has been shown to correct glucose intolerance, insulin
resistance, and hypertriglyceridemia in ESRD patients on dialysis
(32).
One of the common consequences of altered calcium and phosphorus homeostasis resulting from these changes in calciotropic hormones is hyperphosphatemia and an elevated calcium x phosphate products that are often difficult to control and that are associated with calcification of soft tissues, including the aorta, coronary, and other medium sized arteries. It is therefore not surprising that one marker of this dysfunctional calcium/phosphorus regulation, hyperphosphatemia, is associated with a significantly increased risk of mortality in ESRD (35). Attempts to correct serum PTH concentrations to 100 to 300 pcg/ml, hyperphosphatemia to less than 6.5 mg/dl, and keeping calcium x phosphate products in the range of 50 to 60 must begin early in the course of renal failure, well before the need for dialysis. There are numerous calcium supplements and vitamin D analogs as well as a novel non-aluminum-containing phosphate binder that are available for use. However, one must be careful not to suppress PTH excessively or to produce hypercalcemia or hypervitaminosis D for these can also contribute to metastatic vascular calcification; once established, such calcification is rarely reversed.
Taken together, these changes in PTH and vitamin D status and calcium/phosphorus control, either through direct or permissive effects on cardiac metabolism, glucose intolerance, hypertension, dyslipoprotenemia, vascular smooth muscle hypertrophy and arterial calcification, and LVH, contribute significantly to the sustained high rates of morbidity and mortality from cardiac dysfunction, atherosclerosis, and CVD seen in uremia. The ubiquity of this metabolic derangement, practically unique to renal failure, may also explain why the benefits of modifying more traditional risk factors have not been unequivocally seen in ESRD as they have in the non-ESRD population.
Inflammation
Increasingly, atherosclerosis and acute coronary events are being viewed
more as a consequence of inflammation and less as simply the result of
vascular lipid accumulation. The inflammation is thought to result from
processes that induce vascular endothelial dysfunction, thus leading to the
production of vasoactive substances, cytokines, thromboxanes, and growth
factors and to the accumulation of macrophages and T lymphocytes in
atherosclerotic lesions (36).
One such marker of this process is the acute phase reactant C-reactive protein
(CRP). Other inflammatory markers include serum amyloid A, inerleukin-6, and
intercellular adhesion molecule-1. Several studies have shown a strong
association between elevated CRP concentration and coronary artery risk,
particularly in those with previous myocardial infarction and unstable angina.
It is also a strong predictor of fatal myocardial infarction
(37).
CRP has also been observed to be elevated in hemodialysis patients, in association with an atherogenic lipoprotein profile. It was also a strong predictor of death from cardiovascular events (38). Elevated concentrations of numerous cytokines that mediate inflammatory processes have been observed in hemodialysis patients. The reasons for this are uncertain but could relate to biocompatibility of the dialyzer membrane; less biocompatible, unmodified cellulosic membranes have greater cytokine-generating potential and have been associated with greater patient all-cause as well as coronary mortality (39). In addition, exposure of dialysis patients to numerous bacterial infections as well as chronic inflammatory reactions from internal, artificial, or in-dwelling vascular access devices may contribute. With respect to infection, it is believed that only chronic infections with herpes simplex virus-1 and Chlamydia have been associated with increases of coronary heart disease, at least in non-ESRD populations.
In transplant patients, inflammation produced by chronic rejection might contribute to CVD events. There is also an association with frequency of acute rejection episodes (40). Whether this is related to the high corticosteroid doses used to suppress rejection is uncertain. However, steroid use is much reduced since the advent of newer antirejection medications. These data suggest that in ESRD, chronic inflammation of diverse causes may contribute to the excess CVD mortality seen in this group. Although measurements of CRP and other acute phase reactants may be useful prognostic indicators in patients with acute coronary syndromes, additional studies will be needed to determine their value as markers for atherosclerosis risk.
Dialysis as a Risk Factor
Although hemodialysis itself is not widely believed to be a promoter of
atherogenesis, its effects on inflammation might suggest such a role. However,
the hemodynamic effects of hemodialysis do contribute to myocardial ischemia
that often occurs during a dialysis session. The reasons for this include
increased heart rate and decreased coronary filling time, leading to reduce
coronary blood flow and to decreased tissue oxygen delivery resulting from a
pH-mediated enhancement of oxygen affinity for hemoglobin (Bohr effect). When
coupled with the high prevalence of LVH, anemia, reduced coronary vasodilator
reserve, and underlying CAD, hemodialysis can simultaneously reduce myocardial
oxygen delivery at a time when the increased heart rate is producing a greater
myocardial oxygen requirement. This mismatch between oxygen supply and demand
may account not only for the many clinically apparent cardiac events occurring
during dialysis but also for episodes of silent ischemia that have been
recorded during hemodialysis using ambulatory ECG monitoring
(41,42).
There are other important factors that may also contribute to myocardial ischemia. For example, as noted above, the nature of the dialyzer membrane may have a significant impact on acute coronary events and their outcome. The use of low concentrations of dialysate calcium decreases cardiac contractility and may predispose patients to lower BP and to hypotensive episodes with attendant risks for ischemia and arrhythmia (43). The intermittent nature of hemodialysis has been associated with increased rates of sudden and cardiac deaths perhaps partly as a consequence of volume overload that produces increased myocardial wall stress, especially when coupled with the previously mentioned hemodynamic effects of dialysis. Moreover, inadequate dialysis is associated with higher mortality. As a result of the foregoing, there is increasing interest in dialysis sessions of longer duration and with shorter interdialytic intervals, and many centers are studying the benefits of nightly hemodialysis. However, currently there is no broad body of evidence to show that such changes in the hemodialysis prescription will reduce cardiovascular morbidity and mortality. It also remaisn to be seen whether avoidance of low dialysate calcium can also reduce cardiovascular events. However, unless hypercalcemia is a problem, there is no justification for the use of low-calcium dialysate.
Peritoneal dialysis is also associated with a high risk for cardiovascular mortality. The reasons for this are complex. In the past, diabetics and patients with severe CVD were more often referred for this modality, but that is not the case now. The use of acetate in the dialysate may affect lipoprotein profiles and thus be atherogenic. Similarly, the high prevalence of adynamic bone disease in this group could predispose them to a greater risk for vascular calcification with attendant cardiovascular complications.
In summary, identification and management of risk factors for CAD early in the course of renal insufficiency and early detection of the presence of CAD itself have the potential to reduce fatal and nonfatal cardiovascular events in ESRD patients. In an era when late referral for nephrologic care is common, thus, in part, contributing to the high rate of cardiovascular complication seen in ESRD, achieving a goal of early referral will be difficult and will require nephrologists to work with non-nephrologists to manage pre-ESRD patients and to educate them about the importance of early intervention and referral.
|
Silent Ischemia, Occult CAD, and Nonatherosclerotic Coronary Disease: Risks for Cardiovascular Events in ESRD |
|---|
|
TopIntroductionCAD Risk Factors in...Silent Ischemia, Occult CAD,...ConclusionReferences |
|---|
The significance of silent myocardial ischemia is difficult to assess, particularly in a patient who is younger than 50 yr and does not have a history of ischemic heart disease. In such patients, the presence of a positive myocardial perfusion scan may require confirmation by coronary arteriography. Positive stress-perfusion scans or ischemic ECG findings on ambulatory monitoring have been noted in approximately 2 to 3% of the non-ESRD population (44). However, silent ischemia is detected more often in those with histories of myocardial infarction or chronic stable angina and in those high-risk patients, described in the preceding paragraph, and carries a more ominous prognosis than in those with apparent low risk. In these patients, data suggest that future cardiovascular events depend more on severity and number of coronary vessels involved than on the presence of symptoms.
The prevalence of silent myocardial ischemia in ESRD patients is uncertain, but given the demographics and the clustering of risk factors in ESRD, one must suppose that it is more prevalent than in the non-ESRD population. Several small studies using ambulatory ECG monitoring during hemodialysis showed a prevalence of silent ischemia and occult CAD of approximatley 33% (range, 15 to 100%) (45). Some data suggest that its occurrence may be associated with an increase in cardiovascular events, but the numbers of patients studied have been too small to draw a definitive conclusion.
Occult CAD is usually found when coronary artery calcification is seen or suspected by chest x-ray, ECG, echocardiogram, or computed tomography scan of the chest or when coronary angiography is done for evaluation for other cardiac disorders or for preoperative evaluation. In ESRD, this is seen most often in patients with peripheral vascular disease and in diabetics, in whom its presence is a major determinant of survival. In ESRD, it has been found in approximately one third of patients. Occult coronary disease can be discovered without resorting to coronary angiography. The use of noninvasive techniques such as electron beam computed tomography (EBCT) detects the presence of coronary artery calcification and thereby the presence of coronary atherosclerosis. Although it cannot determine the degree of coronary artery occlusion, the severity of calcification determined by EBCT does predict a population at high risk for silent myocardial ischemia (46). However, EBCT has not been found to be an accurate predictor of cardiovascular events in high-risk asymptomatic adults (47). Thus, when appropriate, the use of ECG stress testing using dipyridamole or adenosine coupled with myocardial perfusion scanning with thallium or sestamibi and possibly echocardiography will be the most specific and sensitive methods of determining the presence of silent myocardial ischemia and the further need for coronary angiography. The use of ambulatory ECG may be useful, but the high prevalence of LVH makes interpretation of the ECG alone difficult even if it is performed during the stress of hemodialysis.
There is also a subgroup of patients who may or may not have symptoms of myocardial ischemia associated with positive ECG or perfusion scand in the absence of significant narrowing of a major coronary artery. This has been noted in approximately 25 to 30% of patients (9). This circumstance is often triggered by hypertensive crises or by profound hypotension and tachycardia often occurring during dialysis. These patients are usually younger, more often African American, with histories of hypertension, and a high prevalence of LVH and more severe anemia. As noted previously, this is probably related to the loss of coronary vasodilator reserve, possibly related to alterations in the structure, function, and number of myocardial arterioles producing a greater susceptibility to myocardial ischemia and to cardiovascular mortality.
The foregoing raises questions about how extensively to evaluate the heart in ESRD patients given their propensity for cardiovascular events. This will depend on a careful assessment of potential risk. Certainly not every patient needs ECG stress testing, ambulatory ECG monitoring, or coronary angiography, including patients in whom occult CAD or silent ischemia has been revealed. In fact, coronary angiography, because of its own inherent risks, should be reserved for clinical situations in which an intervention such as coronary bypass grafting (CABG) or percutaneous coronary angioplasty (PTCA) is contemplated. Figure 2 presents an approach to evaluating asymptomatic CAD in renal failure.
|
One reason to identify dialysis patients who are likely to suffer cardiovascular events is to reduce their occurrence when patients are placed in high-risk situations. One important circumstance is surgery, to which ESRD patients are exposed often. It is widely known that patients with CAD have a high risk for intra- and perioperative cardiac events and death. Such patients are older and have signs of congestive heart failure and CAD. Their incidence of perioperative infarction is approximately 4 to 5% and between 2 and 20% during the 2 yr after surgery in the general population (48,49). In ESRD, such data are unavailable, but one might expect that the results would at best be the same. Thus, in such high-risk patients, further assessment of myocardial perfusion and delineation of coronary anatomy may be helpful in deciding a medical management plan for the pre- and postsurgical period. Although the use of long-acting nitrates can decrease myocardial ischemic episodes, one might choose in addition to use ß-blockers before and immediately after surgery, a strategy that has been shown to reduce immediate and long-term postoperative cardiovascular events (49). One might also consider, as prophylaxis, CABG or coronary angioplasty with stent placement before undertaking the needed surgery such as is often done in diabetics before renal transplantation. However, there have been no prospective, randomized studies in this setting to evaluate whether these invasive prophylactic measures, which have their own morbidity and mortality, actually reduce fatal and nonfatal cardiovascular events.
Symptomatic CAD
In ESRD patients, the management of stable and unstable angina is
approximately the same as in the non-ESRD population
(Figure 3) and consists of
nitrates to improve coronary flow, ß-blockers to decrease heart work and
oxygen demand, and, if indicated, calcium-channel blockers to vasodilate
coronary arteries and to reduce BP. Platelet inhibition with aspirin,
ticlopidine, or glycoprotein IIa/IIIb antagonists is effective, with the last
more likely to be used with unstable angina and as an adjunct to angioplasty
with or without stent placement. The use of these antiplatelet drugs alone or
together with unfractionated heparin can significantly reduce the number of
myocardial infarctions or deaths
(50). The use of
unfractionated heparin and aspirin as antithrombin therapy is a standard
practice. Low-molecular-weight heparins have also been variably effective in
unstable angina. Thrombolytic therapy should be reserved for patients with
acute myocardial infarction. Warfarin has been shown to be at least as
effective as aspirin in preventing recurrence or death after an initial
myocardial infarction. Antithrombin therapy, especially with warfarin,
presents added risks for bleeding complications in hemodialysis patients, who
often receive heparin during their dialysis session. In these patients, close
attention to prothrombin time is essential; it may also be necessary to avoid
or minimize the use of heparin during dialysis.
|
Failure of medical management may ultimately necessitate CABG or angioplasty to prevent a first myocardial infarction or a recurrence. CABG is frequently performed in ESRD patients with a reportedly "acceptable" perioperative mortality. However, a review of numerous small series reveal that the perioperative death risk varies between 1 and 25% (51). A recent large study in ESRD patients showed a perioperative mortality of approximately 12.5% or approximately threefold greater than in non-ESRD patients (51). Percutaneous coronary angioplasty is a less invasive alternative that has approximately half the periprocedure mortality as CABG but that is associated with higher recurrence of cardiovascular events and a greater need for repeat procedures because of restenosis. Despite a higher initial mortality rate, patients undergoing CABG have a longer overall survival than those with PTCA (51,52,53). However, it is uncertain what fraction of those who have PTCA had concomitant stent placement, because PTCA + stent is associated with a lower incidence of restenosis, less need for revascularization, and fewer episodes of angina (54).
|
Conclusion |
|---|
|
TopIntroductionCAD Risk Factors in...Silent Ischemia, Occult CAD,...ConclusionReferences |
|---|
|
Acknowledgments |
|---|
|
Footnotes |
|---|
|
References |
|---|
|
TopIntroductionCAD Risk Factors in...Silent Ischemia, Occult CAD,...ConclusionReferences |
|---|
rd O, Nordrehaug JE, Refsum H,
Ueland PM, Farstad M, Vollset SE: Plasma homocysteine levels and mortality in
patients with coronary artery disease. N Engl J Med337
: 230-236,1997This article has been cited by other articles:
 |
|
 |
|
  M. Rodriguez-Garcia, C. Gomez-Alonso, M. Naves-Diaz, J. B. Diaz-Lopez, C. Diaz-Corte, J. B. Cannata-Andia, and the Asturias Study Group Vascular calcifications, vertebral fractures and mortality in haemodialysis patients Nephrol. Dial. Transplant., August 25, 2008; (2008) gfn466v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Doherty, L. A. Fitzpatrick, D. Inoue, J.-H. Qiao, M. C. Fishbein, R. C. Detrano, P. K. Shah, and T. B. Rajavashisth Molecular, Endocrine, and Genetic Mechanisms of Arterial Calcification Endocr. Rev., August 1, 2004; 25(4): 629 - 672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Tonelli, L. Moye, F. M. Sacks, B. Kiberd, G. Curhan, and for the Cholesterol and Recurrent Events (CARE) Tr Pravastatin for Secondary Prevention of Cardiovascular Events in Persons with Mild Chronic Renal Insufficiency Ann Intern Med, January 21, 2003; 138(2): 98 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Danovitch, S. Hariharan, J. D. Pirsch, D. Rush, D. Roth, E. Ramos, R. C. Starling, C. Cangro, and M. R. Weir Management of the Waiting List for Cadaveric Kidney Transplants: Report of a Survey and Recommendations by the Clinical Practice Guidelines Committee of the American Society of Transplantation J. Am. Soc. Nephrol., February 1, 2002; 13(2): 528 - 535. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
